Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

plied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either GPC Biotech or Pharmion. Forward-looking statements speak only as of the date on which they are made and neither GPC Biotech nor Pharmion undertakes any obligation to update these forward-looking statements, even if new information becomes available in the future.

The scientific information discussed in this press release related to satraplatin is investigative. Satraplatin has not yet been approved by the FDA in the U.S., the EMEA in Europe or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated.

CONTACT: Breanna Burkart, or Anna Sussman, Directors, Investor Relationsand Corporate Communications, both of Pharmion Corporation,+1-720-564-9150; or Martin Braendle, Director,
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:9/19/2014)... -- According to the new research ... Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, Musculoskeletal) ... Forecast to 2019" published by MarketsandMarkets, the global Physiotherapy ... by 2019 from $14,240.0 Million in 2014, at ... Browse 74 market data tables and ...
(Date:9/19/2014)... 19, 2014 The American Association for Homecare ... and Manufacturing has joined the AAHomecare Corporate Partner Program. ... Diamond have been actively involved in AAHomecare for ... has quickly grown into a major global manufacturer of ... allows AAHomecare to increase efforts on behalf of the ...
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
(Date:9/22/2014)... September 22, 2014 One key emerging ... Vendors are investing in R&D to develop new and ... orthopedic biomaterial implants. The introduction of third-generation orthopedic biomaterials ... targeted drugs will increase the growth of the market ... Orthopedic Biomaterials market to grow at a CAGR ...
(Date:9/22/2014)... California (PRWEB) September 22, 2014 Plugin ... of ProSparkle. A fully customizable 3D particle emitter made ... “Adding the ProSparkle particle emitter plugin to a video ... Christina Austin, CEO of Pixel Film Studios. “ProSparkle gives ... described as cool” , With ProSparkle users are given ...
(Date:9/22/2014)... The Ruby Report was launched by the publisher ... in Louisville, Kentucky. This release followed the May 6, ... attended by 60 people from the local area. ... while conducting her research, what drove her to study ... what she believes companies can do to be successful ...
(Date:9/21/2014)... The prevalence of preterm birth the birth of ... is a significant health problem that has increased over ... for Disease Control and Prevention (CDC), preterm birth affects ... eight born in the U.S. While medical care has ... ways to positively impact the neurodevelopmental outcomes of preterm ...
(Date:9/21/2014)... Hastings and Hastings, a professional personal ... for aggressively discounted accident victim attorney’s fees. With an ... each year, it is more important than ever before ... fees as a way to enjoy more of their ... a frontrunner when it comes to delivering quick and ...
Breaking Medicine News(10 mins):Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 2Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 3Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 4Health News:Announcing a new ProSparkle Particle Emitter Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 3
... SHORT HILLS, N.J., March 25 The Christopher & ... finding cures and treatments for spinal cord injuries and ... the United States House of Representatives for passing the ... of H.R. 146, the Omnibus Public Land Management Act. ...
... children write about benefits of running; top essayists honored ... 25 Financial services leader ING today selected three ... chronicled their accomplishments as participants in the ING Run ... middle schools.The top three essays were submitted by the ...
... Study in mice reports a more powerful immune response than ... Imagine how much nicer it would be to get vaccinated ... a needle. , That might someday be the case, ... vaccine using probiotics, which are healthy bacteria found in dairy ...
... effort to halt insurer scheme that shifts medical costs ... an expansion of its ongoing effort to expose and ... and physicians of proper reimbursement, the American Medical Association ... that filed a class action lawsuit against WellPoint, Inc., ...
... CheckbookMILWAUKEE, March 25 AARP The Magazine ... more than 34 million readers, today debuted a ... the U.S. by geographic area. ... of two Wisconsin hospitals to achieve this recognition. ...
... Calif., March 25 The nation,s largest organization of ... insurance industry to stop denying coverage to sick people ... insurance trade lobby America,s Health Insurance Plans and Blue ... to those with pre-existing conditions - but only if ...
Cached Medicine News:Health News:Christopher & Dana Reeve Foundation Applauds Historic Passage of the Christopher and Dana Reeve Paralysis Act 2Health News:Christopher & Dana Reeve Foundation Applauds Historic Passage of the Christopher and Dana Reeve Paralysis Act 3Health News:ING Names Winners of 'ING Run For Something Better' Student Essay Contest 2Health News:ING Names Winners of 'ING Run For Something Better' Student Essay Contest 3Health News:ING Names Winners of 'ING Run For Something Better' Student Essay Contest 4Health News:ING Names Winners of 'ING Run For Something Better' Student Essay Contest 5Health News:Oral Yogurt 'Vaccine' Could Blunt Ouch Factor 2Health News:AMA Announces Physician Class Action Against WellPoint 2Health News:AARP Magazine Lists Aurora St. Luke's Medical Center Among the 126 Best Hospitals in the United States 2Health News:Nurses Blast 'Cruel Ruse' by Insurance Giants to Cover Patients as Deal for Forcing Americans to Buy Insurance 2
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
... The Thomson Clinical Xpert™ for PDAs ... tool. The Thomson Clinical Xpert puts authoritative ... the hands of physicians and other prescribers, ... to make important decisions at the point ...
For immediate disabling...
The 3-chip MediLive Trio Eye video camera is built to adapt to changing conditions during ophthalmic surgery with features designed for workflow optimization and maximum image quality....
Medicine Products: